BofA has revised its outlook on Agilent Technologies (A, Financial), reducing the price target from $156 to $128 while maintaining a Neutral rating on the stock. The adjustment reflects growing apprehension in the Life Sciences and Diagnostic Tools sectors, particularly as the companies face multiple policy challenges.
These concerns stem from ongoing shifts in policy introduced by the previous U.S. administration, which include potential reductions in funding from the National Institutes of Health and the impact of global tariffs. Additionally, broader macroeconomic factors, particularly uncertainties related to China, are contributing to the negative sentiment as these firms prepare to report their earnings.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Agilent Technologies Inc (A, Financial) is $146.74 with a high estimate of $165.00 and a low estimate of $115.00. The average target implies an upside of 40.24% from the current price of $104.64. More detailed estimate data can be found on the Agilent Technologies Inc (A) Forecast page.
Based on the consensus recommendation from 20 brokerage firms, Agilent Technologies Inc's (A, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Agilent Technologies Inc (A, Financial) in one year is $144.03, suggesting a upside of 37.64% from the current price of $104.64. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Agilent Technologies Inc (A) Summary page.
